Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
Exagen Inc. (XGN)
Last exagen inc. earnings: 3/25 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic Lupus Erythematosus (SLE) and rheumatoid arthritis (RA) biomarkers, to be incorporated into the AVISE CTD platform. Collectively, these new biomarkers will further improve the clinical utility of AVISE CTD, providing clinicians with the information they need to definitively diagnose patients and shorten their autoimmune diagnostic journeys. Since 2012, AVISE CTD has delivered diagnostic clarity where overlapping clinical symptoms and ambiguous disease states make it difficult to arrive at a differential diagnosis of a connective tissue disease (CTD). A lack of diagnostic clarity may lead to serial and repeat testing, increased morbidity, worsening mortality rates and growing healthcare costs. “The AVISE CTD enhancements are a direct result of our continuing commitment to develop and deliver
Show less
Read more
Impact Snapshot
Event Time:
XGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XGN alerts
High impacting Exagen Inc. news events
Weekly update
A roundup of the hottest topics
XGN
News
- Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD [Yahoo! Finance]Yahoo! Finance
- Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTDGlobeNewswire
- Mindera Health™ Welcomes New Vice President of Sales [Yahoo! Finance]Yahoo! Finance
- Innovative Clinical Biomarkers for SLE and RA: Advancing Autoimmune Diagnostics, Upcoming Webinar Hosted by XtalksPR Web
- Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform [Yahoo! Finance]Yahoo! Finance
XGN
Earnings
- 11/12/24 - Beat
XGN
Sec Filings
- 12/12/24 - Form SC
- 11/27/24 - Form 4
- 11/19/24 - Form 4
- XGN's page on the SEC website